USA-based company ImmunoGen, a specialist in the field of antibody-drug conjugates (ADCs) for the treatment of cancer, has appointed Isabel Kalofonos as senior vice president and chief commercial officer. 24 April 2023
Danish clinical-stage retinal diseases biotech Breye Therapeutics today announced the appointment of Peter Adamson as chief scientific Officer (CSO). 20 April 2023
Engimmune Therapeutics, a biotech developing novel T-cell receptor (TCR)-based therapies, has announced the appointment of Lars Nieba as chief executive. 19 April 2023
Long-term incumbent Dr Roy Vagelos will retire from his role as chairman of US biotech Regeneron Pharmaceuticals’ board of directors and will not stand for re-election. 18 April 2023
US biotechnology company Bicycle Therapeutics , which pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, has announced the appointment of Dr Santiago Arroyo as chief development officer, effective March 31. 6 April 2023
French clinical-stage biotech Abivax has appointed Marc de Garidel as chief executive (CEO) and interim board chairman of the company, effective May 5, 2023. 6 April 2023
US biotech major Biogen has appointed Adam Keeney as executive vice president, head of corporate development effective April 17, 2023, adding a new face to its business development team. 5 April 2023
Wuppertal, Germany-based infectious disease drug developer AiCuris Anti-infective Cures today announced the appointment of Larry Edwards as chief executive (CEO), effective April 1, 2023. 4 April 2023
Austrian drug discovery company Quantro Therapeutics has appointed Dr Michael Bauer as the firm’s chief executive (CEO), effective May 1, 2023. 4 April 2023
PTC Therapeutics announced on Friday day that Stuart Peltz, chief executive (CEO) of the US biopharma company, is stepping down after 25 years. 27 March 2023
US biopharma Inozyme Pharma has announced that founding chief executive officer Axel Bolte will retire from his current role, to be replaced by Douglas Treco. 24 March 2023
Clay Siegall is leaping back into the biotech world as chief executive and president of Morphimmune, a pre-clinical biotechnology company focused on developing targeted oncology therapeutics based in Seattle, USA. 23 March 2023
Beam Therapeutics, a US biotech developing precision genetic medicines through base editing, has named Gopi Shanker its chief scientific officer (CSO). 22 March 2023
Effective March 11, Gustavo Pesquin will become the next chief executive (CEO) of Asklepios BioPharmaceutical (AskBio), which was acquired in 2020 by Germany’s Bayer. 9 March 2023
The strategic venture capital unit of US healthcare giant Johnson & Johnson (NYSE: JNJ) has put its weight behind a $100 million boost for a new precision medicine company. 8 March 2023
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024